405 related articles for article (PubMed ID: 24402960)
1. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
2. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
3. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
5. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
Schmidinger M; Wittes J
Curr Opin Urol; 2015 Sep; 25(5):395-401. PubMed ID: 26148069
[TBL] [Abstract][Full Text] [Related]
7. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
9. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
[No Abstract] [Full Text] [Related]
10. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Sun M; Trinh QD; Perrotte P; Karakiewicz PI
Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500
[No Abstract] [Full Text] [Related]
11. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Ouzaid I; Rini B
Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761
[No Abstract] [Full Text] [Related]
12. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib versus sunitinib in renal cancer.
Casper J; Schumann-Binarsch S; Köhne CH
N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224638
[No Abstract] [Full Text] [Related]
14. Pazopanib versus sunitinib in renal cancer.
Wittes J
N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224637
[No Abstract] [Full Text] [Related]
15. Pazopanib versus sunitinib in renal cancer.
Ramaekers R; Tharnish M; Copur MS
N Engl J Med; 2013 Nov; 369(20):1968-9. PubMed ID: 24224636
[No Abstract] [Full Text] [Related]
16. Pazopanib versus sunitinib in renal cancer.
Motzer RJ; McCann L; Deen K
N Engl J Med; 2013 Nov; 369(20):1970. PubMed ID: 24224635
[No Abstract] [Full Text] [Related]
17. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
18. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
20. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]